Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update
Chemomab Therapeutics (Nasdaq: CMMB), a clinical stage biotech company focused on fibro-inflammatory disease treatments, announced it will release its Q3 2024 financial results and business update on November 14, 2024, at 7:00 am ET. Investors interested in discussing the results after the release can contact the company via IR@chemomab.com.
Chemomab Therapeutics (Nasdaq: CMMB), una società biotecnologica in fase clinica focalizzata sui trattamenti per le malattie fibro-infiammatorie, ha annunciato che rilascerà i suoi risultati finanziari del terzo trimestre 2024 e un aggiornamento aziendale il 14 novembre 2024, alle 7:00 ora dell'Est. Gli investitori interessati a discutere i risultati dopo la pubblicazione possono contattare l'azienda via IR@chemomab.com.
Chemomab Therapeutics (Nasdaq: CMMB), una compañía biotecnológica en etapa clínica centrada en tratamientos para enfermedades fibro-inflamatorias, anunció que dará a conocer sus resultados financieros del tercer trimestre de 2024 y una actualización empresarial el 14 de noviembre de 2024, a las 7:00 am ET. Los inversores interesados en discutir los resultados después de la publicación pueden contactar a la compañía a través de IR@chemomab.com.
Chemomab Therapeutics (Nasdaq: CMMB), 섬유-염증 질환 치료에 집중하는 임상 단계 생명공학 회사가 2024년 3분기 재무 결과 및 사업 업데이트를 2024년 11월 14일 오전 7시에 발표할 것이라고 발표했습니다. 발표 후 결과에 대해 논의하고 싶은 투자자는 IR@chemomab.com을 통해 회사에 연락할 수 있습니다.
Chemomab Therapeutics (Nasdaq: CMMB), une entreprise biopharmaceutique en phase clinique axée sur le traitement des maladies fibro-inflammatoires, a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 et une mise à jour de l'entreprise le 14 novembre 2024 à 7h00, heure de l'Est. Les investisseurs intéressés à discuter des résultats après la publication peuvent contacter l'entreprise à l'adresse IR@chemomab.com.
Chemomab Therapeutics (Nasdaq: CMMB), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Behandlung von fibro-inflammatorischen Erkrankungen konzentriert, gab bekannt, dass es seine finanziellen Ergebnisse für das dritte Quartal 2024 und ein Unternehmensupdate am 14. November 2024 um 7:00 Uhr ET veröffentlichen wird. Investoren, die an einer Diskussion der Ergebnisse nach der Veröffentlichung interessiert sind, können das Unternehmen unter IR@chemomab.com kontaktieren.
- None.
- None.
TEL AVIV, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (“Chemomab” or the “Company”), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced the company will issue a press release reporting its third quarter 2024 financial results and providing a business update on November 14, 2024, at 7:00 am Eastern Time.
Investors who would like to discuss the financial results or business update after the press release has been issued are invited to contact the company at IR@chemomab.com.
About Chemomab Therapeutics Ltd.
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a first-in-class dual activity monoclonal antibody that neutralizes CCL24 activity and has demonstrated disease-modifying potential. In clinical and preclinical studies, CM-101 has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from four clinical trials of CM-101 in patients. Based on recent promising data from its Phase 2 SPRING trial in the rare liver disease primary sclerosing cholangitis (PSC), the company expects two milestones in early 2025, including FDA feedback on the design of its planned PSC Phase 3 registrational trial and data from the SPRING trial open label extension. CM-101 has received FDA and EMA Orphan Drug and FDA Fast Track designations for PSC. Chemomab’s CM-101 program for the treatment of systemic sclerosis is Phase 2-ready with an open U.S. IND. For more information, visit: chemomab.com.
Contact:
Media & Investors:
Chemomab Therapeutics
Barbara Lindheim
Consulting Vice President
Investor & Public Relations,
Strategic Communications
Phone: +1 917-355-9234
barbara.lindheim@chemomab.com
IR@chemomab.com
FAQ
When will Chemomab Therapeutics (CMMB) release Q3 2024 earnings?
How can investors discuss Chemomab's (CMMB) Q3 2024 results with the company?
What is Chemomab Therapeutics' (CMMB) main business focus?
